Behavioral sciences (Basel, Switzerland)
April 30, 2026
Dylan Briggs, Thomas B Sease, Ruthie Menou et al.
Mystical experiences are characterized by a profound sense of interconnectedness and transcendence of ordinary reality. These experiences can facilitate feelings of connectedness with oneself and others and have been documented as leading to significant positive changes in thoughts, emotions, and behavior. The purpose of the present study was to evaluate the extent to which the four mindfulness...
Psychopharmacology
April 29, 2026
Anne-Fiona Griesfeller, Lotte Kooman, Lilian Kloft-Heller et al.
RATIONALE: Reports of resurfaced repressed memories during psychedelic experiences have circulated for decades and still emerge today. However, the veracity of repressed memories remains debated, and the mechanisms through which psychedelics might recover alleged repressed memories are unclear. OBJECTIVES: This scoping review aimed to provide an overview of the literature on repressed memory in...
medRxiv Preprint Server
April 28, 2026
Sandeep M. Nayak, Nathan D. Sepeda, Matthew Nielsen Dick et al.
preprint
Background Psilocybin has increasingly been studied as a therapeutic for psychiatric and neurologic conditions, yet comprehensive cardiovascular safety data are limited. Current trials often exclude individuals with blood pressure ≥140/90 mmHg, criteria established conservatively without robust empirical support.
Current Neuropharmacology
April 28, 2026
Hongshuang Wang, Xiaobing Li, Feng Yu et al.
The integration of psychedelics and music in therapeutic settings is gaining recognition for its potential to enhance mental health outcomes. This review synthesizes current evidence on the neurobiological mechanisms underlying this synergy, focusing on receptor-level pathways (e.g., 5-HT2A receptor agonism, BDNF-TrkB signaling) and neural circuit dynamics (e.g., default mode network...
Journal of Medical Internet Research
April 27, 2026
Karilynn M Rockhill, Elizabeth A Bemis, Nicole Schow et al.
2 citations
Mainstays of pharmacoepidemiology are large, representative, behavioral surveys, which focus on many drugs with few detailed behaviors. Smaller, targeted studies measure drug-specific patterns but without explicit generalizability assumptions; the evidence generated is narrow. In this cross-sectional survey study, we outline an estimation framework based on data fusion and combine two surveys:...
Trends in Psychiatry and Psychotherapy
April 25, 2026
Alberto Barbieri
Personality disorders (PDs) are characterized by rigid and maladaptive patterns of self- and interpersonal functioning, leading to high clinical burden and limited treatment outcomes. Schema Therapy (ST), an integrative psychotherapy rooted in cognitive-behavioral principles, conceptualizes PDs in terms of Early Maladaptive Schemas (EMS)-pervasive cognitive-affective structures formed through...
AJNR. American journal of neuroradiology
April 24, 2026
Joga Chaganti, Krista J. Siefried, Veda S Vyakaranam et al.
Methamphetamine (MA) use disorder is associated with widespread disruption of large-scale brain networks involved in cognitive control, attention, and salience processing. Resting-state functional MRI (rs-fMRI) provides a means to characterize these alterations; however, little is known about the capacity for functional network reorganization following targeted intervention. The purpose of this...
Communications Biology
April 24, 2026
Tatum Askey, Daniel Allen-Ross, Daniil Luzyanin et al.
Chronic pain states remain challenging to control with current drug therapies. Here, we demonstrate that a single dose of psilocybin produces a sustained anti-nociceptive effect in chronic neuropathic pain models in male and female mice, mediated primarily by 5-HT2A receptors. Critically, psilocybin significantly potentiates the analgesic efficacy of gabapentin, a standard-of-care treatment,...
Research Square
April 23, 2026
Leah M Salinsky, Joshua L Fox, Kyra C Diaz et al.
Polysubstance use involving psychostimulants and opioids is increasingly prevalent and associated with elevated overdose risk, relapse vulnerability, and poor treatment outcomes. However, the neurobehavioral consequences of opioid-stimulant use remain poorly understood. We evaluated whether repeated methamphetamine-fentanyl polysubstance treatment disrupts social preference during withdrawal,...
Am J Psychiatry
April 22, 2026
Kevin H. Yang, Avery Eun, Joseph J Palamar
Prevalence and Correlates of Past-Year Psilocybin Use in the United States.
bioRxiv : the preprint server for biology
April 22, 2026
Cory A. Knox, Samuel C Woodburn, Amelia D. Gilbert et al.
The classic psychedelic psilocybin elicits long-lasting neural plasticity and behavioral effects, but prior studies largely examined stress-naive animals. Using longitudinal imaging, we show that psilocybin increases dendritic spine density in frontal cortical neurons and facilitates fear extinction after chronic restraint stress, demonstrating psilocybin's effects in a translationally relevant...
Gaceta Médica de Caracas
April 22, 2026
Deivid Antonio Cahuasqui-Mendoza
Introduction. Limitations of conventional treatments for depression and anxiety, particularly in treatment-resistant cases, have driven interest in alternative therapeutic approaches. Psilocybin, a serotonergic agonist with demonstrated effects on neuroplasticity and large-scale brain networks, has emerged as a promising therapeutic option. Materials and methods: A systematic review of...
Mental Wellness
April 21, 2026
Mohsen Khosravi, Domenico de Berardis, Massimo Tusconi
This systematic review and meta-analysis synthesized data from 13 clinical trials (n=606) evaluating psilocybin-assisted psychotherapy for major depressive disorder and treatment-resistant depression. Despite early enthusiasm, the pooled standardized mean difference (-0.79, 95% confidence interval: -3.98 to 2.40, p=0.63) revealed no statistically significant overall antidepressant effect, with...
Open Access Indonesian Journal of Medical Reviews
April 21, 2026
Siti Nashria Rusdhy, Andrian Fajar Kusumadewi, Carla Raymondalexas Marchira et al.
Psilocybin-assisted therapy shows promise for depression, though current evidence relies on Phase 2 trials with notable methodological limitations. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating psilocybin-assisted therapy for major or treatment-resistant depression up to February 2024. We evaluated depressive symptom severity using...
Preprints.org
April 20, 2026
Octavian Victor Brinzei
preprint
In the past year, the medical regulation of psilocybin-assisted therapy has expanded across additional international jurisdictions, requiring an update to the original medico-legal synthesis. Newly established or clarified regulatory pathways in New Zealand, Germany, Switzerland, the Czech Republic, and at the United States federal level reflect continued evolution in therapeutic governance....
Zenodo (CERN European Organization for Nuclear Research)
April 19, 2026
H. Tamba
Psilocybin simultaneously holds six contradictory legal classifications across jurisdictions: Schedule I (US federal), Breakthrough Therapy (FDA), legal therapeutic use (Oregon, Colorado), Schedule 8 medical use (Australia), and pending rescheduling review (DEA/HHS). This regulatory fragmentation constitutes a classification cascade—a multi-stage disruption propagated through administrative,...
Science Letters
April 17, 2026
Diana Dias Da Silva, Andreia Machado Brito-Da-Costa, Francisco Sacadura et al.
Background: Psilocybin, a key psychoactive compound found in Psilocybe mushrooms, has gained increasing attention due to its therapeutic potential in neuropsychiatric disorders [1]. However, comparative preclinical data between isolated psilocybin and whole mushroom extracts remain scarce, particularly regarding behavioural reinforcement and peripheral toxicity [2,3]. Objective: To compare the...
Science Letters
April 17, 2026
Beatriz P. Senra, Ricardo Jorge Dinis-Oliveira, Carlos J. A. Ribeiro
Background: Psilocybe cubensis mushrooms contain the tryptamines psilocybin and psilocin, which are recognized for their therapeutic potential in mental health [1]. Additionally, due to their psychedelic effects, these mushrooms are also used for religious and recreational purposes. The increasing use of these tryptamines and other psychoactive substances has led to regulatory measures,...
Science Letters
April 17, 2026
Francisco Sacadura, Cláudia Marques, Andreia Machado Brito-Da-Costa et al.
Background: Psilocybin, the main psychoactive compound found in Psilocybe mushrooms, has gained increasing attention due to its potential therapeutic effects in neuropsychiatric disorders [1]. Beyond its central effects, increasing evidence highlights the relevance of the gut–brain axis, suggesting that psychedelics may also influence intestinal microbiota composition. Whole mushroom extracts...
medRxiv Preprint Server
April 17, 2026
Chiranth Bhagavan, Orwa Dandash, Olivia Carter et al.
preprint
Background Psilocybin is a classic psychedelic that acutely alters brain functional connectivity. These changes are linked to therapeutic doses and subjective effects, with some evidence that changes persist beyond acute drug administration. However, the effects of lower doses on sustained connectivity changes remain unclear.
bioRxiv : the preprint server for biology
April 17, 2026
Pasha A. Davoudian, Quan Jiang, Cory A. Knox et al.
Psychedelics show therapeutic potential for treating psychiatric disorders. While studies have emphasized the roles of cortical pyramidal cells, GABAergic neurons also express serotonin receptors and are therefore likely targets of psychedelics. In this study, we determine the effect of psilocybin on the activity dynamics of major GABAergic cell types in the mouse medial frontal cortex....
Journal of Psychedelic Studies
April 15, 2026
Jean C. Vélez Rodríguez, Yanice Duquesne-Maldonado, Julián M. Hernández Torres et al.
Abstract Background and aims Psilocybin, a psychoactive compound found in fungi commonly referred to as “magic mushrooms,” is consumed for both spiritual and recreational purposes. However, psilocybin use in Puerto Rico remains understudied. This exploratory cross-sectional survey aimed to describe patterns of use, motivations for consumption, explanatory factors, personality traits, and...
Translational Psychiatry
April 14, 2026
Ryan J. Keenan, Rifa T Haque, Xiangjun Jin et al.
Prolonged obesity induces enduring structural changes within neural circuits that contribute to maintaining the body at an elevated/obese body weight. These circuits regulate various mechanisms which can inhibit extreme or persistent weight loss. Therefore, a potential therapeutic strategy to facilitate weight loss is to promote structural plasticity within the brain. Psychedelic compounds,...
Frontiers in Public Health
April 14, 2026
Anthony L. Back, Bonnie A. Mcgregor, Leslie L. Thorn et al.
Introduction: Psilocybin therapy has demonstrated efficacy for cancer-related anxiety and depression, but resource-intensive individual treatment models raise important questions for psychedelic public health about equitable access and scalability. In our prior Phase 1/2 study of group retreat psilocybin therapy for patients with metastatic cancer, we observed partial responders who did not...